BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States
Active, not recruiting
- Conditions
- Post Intensive Care Syndrome (PICS)Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Other: An ICU admission and a temporally related ARDS diagnosis
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 140000
- Registration Number
- NCT06272942
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
An Observational Study to Collect Information on the Safety of Gadolinium-Based Contrast Agents in Patients in India
Active, not recruiting
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging
- Interventions
- Drug: GBCAs
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT06257277
- Locations
- 🇮🇳
Many locations, Multiple Locations, India
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
Phase 2
Active, not recruiting
- Conditions
- Solid Malignant Tumors
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13
- Registration Number
- NCT06246643
- Locations
- 🇫🇷
Hôpital Beaujon - Clichy, Clichy, France
🇫🇷Hopital Claude Huriez - Lille, Lille, France
🇫🇷Hôpital Paul Brousse - Villejuif, Villejuif, France
Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors
- Conditions
- Cancer
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Bayer
- Registration Number
- NCT06238583
- Locations
- 🇺🇦
Many Locations, Multiple Locations, Ukraine
A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A
Recruiting
- Conditions
- Treatment of BleedingProphylaxis of BleedingHemophilia A
- Interventions
- Drug: Damoctocog-alfa-pegol (Jivi, BAY94-9027)
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 600
- Registration Number
- NCT06222697
- Locations
- 🇰🇷
Many Locations, Multiple Locations, Korea, Republic of
A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy VolunteersEGFR MutationAdvanced Non-small Cell Lung CancerHER2 Mutation
- Interventions
- Drug: BAY2927088 coated tablet 10 mgDrug: [14C]-BAY2927088 solution for infusionDrug: [14C]-BAY2927088 oral solution
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8
- Registration Number
- NCT06221475
- Locations
- 🇳🇱
ICON plc, Groningen, Netherlands
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1
Recruiting
- Conditions
- Prostate Specific Membrane Antigen (PSMA) ExpressionAdvanced Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: 225Ac-PSMA-Trillium (BAY3563254)
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 235
- Registration Number
- NCT06217822
- Locations
- 🇨🇦
Cross Cancer Institute, Clinical Trials Unit, Edmonton, Alberta, Canada
🇫🇮Docrates Mehiläinen Syöpäsairaala, Helsinki, Uusimaa, Finland
🇫🇮Tampere University Hospital, Tampere, Finland
A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women
Phase 1
Completed
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenHot Flashes
- Interventions
- Drug: Elinzanetant (BAY3427080)Drug: Placebo to elinzanetant
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64
- Registration Number
- NCT06219902
- Locations
- 🇨🇦
AltaSciences, Mount-Royal, Canada
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
Completed
- Conditions
- Non-metastatic Castration-resistant Prostate CancerNon-metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1800
- Registration Number
- NCT06204302
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Phase 2
Completed
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 106
- Registration Number
- NCT06195930
- Locations
- 🇺🇸
Reid Physician Associates | Cardiology Department, Richmond, Indiana, United States
🇦🇷Instituto de Cardiologia de Corrientes Juana F. Cabral | Corrientes, Argentina, Corrientes, Argentina
🇵🇱Centrum Medyczne Zdrowa, Krakow, Poland
© Copyright 2025. All Rights Reserved by MedPath